Importance: Schizophrenia is a complex syndrome with taxing symptoms and for which
treatment challenges remain. Current dopamine D 2 receptor–blocking antipsychotics have …

Background Patients with first-episode psychosis or early-phase schizophrenia are
susceptible to olanzapine-associated weight gain and cardiometabolic dysregulation. This …

Importance In individuals with schizophrenia, antipsychotic-induced dysfunctions are
frequent but often underexplored in clinical practice. Objective To synthetize the data of …

Background Antipsychotic medication can reduce psychotic symptoms and risk of relapse in
people with schizophrenia and related disorders, but it is not always effective and adverse …

Background Many second-generation antipsychotics (SGAs) are associated with weight
gain and cardiometabolic effects. Antipsychotic-associated weight gain is linked to treatment …

This continuing education supplement is jointly provided by Medical Education Resources
and CMEology. The supplement is supported by an independent educational grant from …

Background Nonadherence/discontinuation of antipsychotic (AP) medications represents an
important clinical issue in patients across psychiatric disorders, including schizophrenia …

Pharmacists have a contribution to make in improving optimising medication use for people
on antipsychotic medication. The rates of prescribing antipsychotics have increased in …

Background Schizophrenia (SZ) and bipolar I disorder (BD-I) are chronic mental health
disorders often treated with antipsychotic medications. This qualitative study sought to better …

Most patients with schizophrenia need life-long treatment. There is therefore a continued
need for effective and tolerable treatment options. A 2-monthly LAI formulation of …